Showing 1321-1330 of 1550 results for "".
- Galderma's Nemolizumab Performs Well in Phase 2b for ADhttps://practicaldermatology.com/news/galdermas-nemolizumab-performs-well-in-phase-2b-for-ad/2460739/Investigational nemolizumab led to rapid and sustained improvements in itch, sleep, and skin lesions in adult patients with uncontrolled moderate-to-severe AD in phase 2 studies published in Journal of the European Academy of Dermatology and Venereology (JEADV) and reported by
- Pediatric Dermatology Incomes Up; Demand Persists: Surveyhttps://practicaldermatology.com/news/pediatric-dermatology-incomes-up-demand-persists-survey/2460735/Median total compensation for pediatric dermatologists has increased 37 percent since 2014, results of The Society for Pediatric Dermatology’s (SPD) latest compensation report show. The
- Hoth Therapeutics’ HT-003 Inhibits Acne Gene TLR2https://practicaldermatology.com/news/hoth-therapeutics-ht-003-inhibits-acne-gene-tlr2/2460538/Hoth Therapeutics, Inc. completed testing on the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes. Initial data from the first phase of the research reports that toll-like receptor 2 (TLR2) is significantly
- Alastin Skincare's INhance Post-Injection Serum Reduces Bruisinghttps://practicaldermatology.com/news/alastin-skincares-inhance-post-injection-serum-reduces-bruising/2460419/Alastin’s Skincare’s INhance Post-Injection Serum with TriHex Technology can help reduce post-injection bruising and swelling, according to a report inthe Journal of Drugs in Dermatology. In
- Promising Data from Dermavant's Phase 2b Study of Tapinarof in Psoriasishttps://practicaldermatology.com/news/promising-data-from-dermavants-phase-2b-study-of-tapinorof-in-psoriasis/2460405/Patients treated with once daily tapinarof 1% demonstrated improvement in PASI75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase
- COVID-19 By the Numbers: May 5 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-may-5-edition/2460375/Sixteen states have significantly reduced COVID-19 restrictions, while 18 have somewhat reduced restrictions, a new analysis from WalletHub reveals. The easing comes as the US reports nearly 70,000 COVI
- New Melanoma Test May Reduce Unnecessary Lymph Node Biopsieshttps://practicaldermatology.com/news/new-melanoma-test-may-reduce-unnecessary-lymph-node-biopsies-1/2460348/A new skin cancer test may reduce up to 42 percent of sentinel lymph node biopsies used in the diagnosis of patients with melanoma, researchers at SkylineDx and Mayo Clinic report. The study appears in
- Proof of Concept Study Supports Dermata’s Topical Delivery Mechanism for Botulinum Toxinhttps://practicaldermatology.com/news/proof-of-concept-study-supports-dermatas-topical-delivery-mechanism-for-botulinum-toxin/2460089/Dermata Therapeutics’ DMT410 (DMT310 + botulinum toxin) performed well in a Phase 1proof of concept study for the treatment of primary axillary hyperhidrosis, the Company reports. DMT410 is a combination regimen for the treatment of skin
- BioPharmX’s BPX-04 Performs Well in Rosacea Trialhttps://practicaldermatology.com/news/biopharmxs-bpx-04-performs-well-in-rosacea-trial/2460078/BioPharmX Corporation ‘s BPX-04, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea, performed well in a Phase 2b clinical trial, the Company reports. In the trial,
- SkinBioTherapeutics Raises Capital to Broaden Applications for Skin Biome Technologyhttps://practicaldermatology.com/news/skinbiotherapeutics-raises-capital-to-broaden-applications-for-skin-biome-technology/2459894/SkinBioTherapeutics raised close to $2M to widen potential applications for their skin biome technology, the company reports. Derived from probiotic bacteria, SkinBioTherapeutics technology is being developed for use in cosmetics, infectio